Corvus Pharmaceuticals CRVS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$13.69M-190% | -$12.32M-1.7% | -$10.16M+74.7% | -$8M-87.7% | $15.19M+366% | ||
| $29K+31.8% | $26K+30.0% | $28K+33.3% | $29K+38.1% | $22K-4.3% | ||
| $2.65M+112% | $1.57M+93.6% | $1.25M+70.4% | $1.26M+63.5% | $1.25M+81.6% | ||
| —— | —— | —— | —— | —— | ||
| $2.21M+273% | —— | -$1.16M-276% | $1.83M+562% | -$1.27M-1,617% | ||
| $499K+242% | $765K+256% | $708K+896% | $1.14M+390% | $146K+44.6% | ||
| -$88K-7.3% | -$88K-110% | -$85K+71.1% | -$83K+71.1% | -$82K+71.1% | ||
| -$599K-11.1% | -$707K+67.5% | -$323K+52.6% | -$389K+32.6% | -$539K-328% | ||
| -$103K-432% | -$74K— | -$72K+79.2% | -$70K+79.4% | $31K+109% | ||
| $865K+28,933% | $3K-99.2% | $226K+83.7% | -$3K— | -$3K— | ||
| -$10.37M-25.5% | -$9.19M-8.6% | -$9.57M-51.3% | -$5.78M-5.4% | -$8.26M-60.2% | ||
| $91K+153% | $25K— | $0— | $113K— | $36K— | ||
| $161.74M+1,998% | $13.42M-34.1% | $31.15M+65.4% | $39.48M+50.1% | $7.71M+66.6% | ||
| $16.98M+41.7% | $24.32M+70.4% | $28.53M+90.9% | $19.29M+119% | $11.99M+159% | ||
| —— | —— | —— | —— | —— | ||
| -$144.85M-3,514% | —— | -$2.62M+32.7% | -$20.3M-16.0% | $4.24M+60,714% | ||
| $189.41M+67,788% | $20K-99.5% | $360K-91.2% | $25K-99.4% | $279K-93.2% | ||
| $190.75M+68,268% | $20K-99.9% | $360K+620% | $35.77M— | $279K— | ||
| $35.53M+1,050% | —— | -$11.82M-16.4% | $9.69M+31.2% | -$3.74M+27.6% | ||
| $17K-94.2% | $261K+7.9% | $459K-12.4% | $334K+49.1% | $291K+92.7% | ||
| -$599K-11.1% | -$707K+67.5% | -$323K+52.6% | -$389K+32.6% | -$539K-328% | ||
| $499K+242% | $765K+256% | $708K+896% | $1.14M+390% | $146K+44.6% | ||
| -$103K-432% | -$74K— | -$72K+79.2% | -$70K+79.4% | $31K+109% | ||
| $865K+28,933% | $3K-99.2% | $226K+83.7% | -$3K— | -$3K— | ||
| $1.76M+251% | —— | -$64K-129% | —— | -$1.17M-1,290% | ||
| $16.98M+41.7% | $24.32M+70.4% | $28.53M+90.9% | $19.29M+119% | $11.99M+159% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$2.01M-10.8% | -$25.13M— | ||
| -$103K-432% | -$74K— | -$72K+79.2% | -$70K+79.4% | $31K+109% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $442.25K-86.8% | $442.25K-86.8% | $442.25K-86.8% | $442.25K-86.8% | ||
| $553K— | —— | —— | —— | —— | ||
| -$10.47M-26.1% | -$9.22M— | -$9.57M— | -$5.89M— | -$8.3M— | ||
| -$10.47M-26.1% | -$9.22M— | -$9.57M— | -$5.89M— | -$8.3M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Corvus Pharmaceuticals generate?
- Corvus Pharmaceuticals (CRVS) generated -$34.9M in operating cash flow over the trailing twelve months.
- What is Corvus Pharmaceuticals's free cash flow?
- After $229.0K of capital expenditures, Corvus Pharmaceuticals's free cash flow was -$35.1M over the trailing twelve months, down 45.7% year over year.
- Where does Corvus Pharmaceuticals's cash flow data come from?
- Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.